ATSG (ATSG) Continues Fleet Modernization with Purchase of Three Boeing 757-200

Air Transport Services Group, Inc. (NASDAQ:ATSG) said today that its aircraft leasing subsidiary has reached agreement with National Air Cargo Group, Inc., for the purchase of three Boeing 757-200 aircraft that have been modified for combi (combined passenger and main-deck cargo) service.

ATSG said it anticipates that its subsidiary, Cargo Aircraft Management (CAM), will take delivery of one of the three 757 combi aircraft in December 2012, and the other two in early 2013.

Joe Hete, President and CEO of ATSG, said, “The purchase of these three 757 combis from National, plus the one 757 combi we already own, will complete our commitment to replace our four McDonnell-Douglas DC-8 combis with more modern fuel-efficient aircraft that better meet the requirements of our principal combi customer, the U.S. Military’s United States Transportation Command (USTRANSCOM). We look forward to providing USTRANSCOM with the improved operating performance and lower costs of the 757, as well as its greater passenger capacity. We are proud to be USTRANSCOM’s sole combi operator, serving primarily remote installations around the world that rely on the combi’s unique cargo and passenger transport capabilities.”

The 757 combis have a 34 percent lower fuel burn, ten more passenger seats and the same number of cargo pallet positions as the DC-8 combis they will replace. The combis will be owned by CAM and leased to and operated by ATSG’s airline subsidiary Air Transport International (ATI), under ATI’s contract with USTRANSCOM. Along with the three aircraft, CAM is also purchasing a spare 757-200 engine and some ancillary aircraft equipment from National.

As part of its fleet modernization program, prior to ATI’s latest combi contract award from USTRANSCOM that took effect in October 2012, CAM purchased a Boeing 757-200 for combi conversion. That aircraft is undergoing certification testing for the Federal Aviation Administration, and is due to complete that process and begin USTRANSCOM service early next year. All three of the National combis were designed and modified to meet or exceed the same FAA and USTRANSCOM requirements, including ETOPS (Extended-range Twin-engine Operational Performance Standards) certification essential for service to USTRANSCOM’s combi destinations.

Upon the retirements of the four DC-8 combis, ATSG’s fleet will consist entirely of 757-200, 767-200 and 767-300 aircraft, all of which require only two crew members, and which share a common pilot type rating.

“This purchase of the National 757 combi aircraft further enhances our position as the world’s largest independent provider of modern, fuel-efficient midsized cargo aircraft to customers around the world,” Hete said. “No other provider can match the flexibility we offer in midsized airlift, whether on a dry-lease, ACMI or charter basis.”

ATSG noted that, as a result of its decision to acquire one of the 757 combis in 2012, it has adjusted its previously disclosed guidance for aircraft-related capital expenditures in 2012 and 2013 to approximately $170 million and $95 million, respectively.

About ATSG

ATSG is a leading provider of aircraft leasing and air cargo transportation and related services to domestic and foreign air carriers and other companies that outsource their air cargo lift requirements. ATSG, through its leasing and airline subsidiaries, is the world’s largest owner and operator of converted Boeing 767 freighter aircraft. Through its principal subsidiaries, including three airlines with separate and distinct U.S. FAA Part 121 Air Carrier certificates, ATSG provides aircraft leasing, air cargo lift, aircraft maintenance services and airport ground services. ATSG’s subsidiaries include ABX Air, Inc.; Airborne Global Solutions, Inc.; Air Transport International, Inc.; Cargo Aircraft Management, Inc.; Capital Cargo International Airlines, Inc.; and Airborne Maintenance and Engineering Services, Inc. For more information, please see www.atsginc.com.

Except for historical information contained herein, the matters discussed in this release contain forward-looking statements that involve risks and uncertainties. There are a number of important factors that could cause Air Transport Services Group’s (“ATSG’s”) actual results to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timely delivery by National Air Cargo Group to Cargo Aircraft Management (“CAM”) of the three Boeing 757-200 combi aircraft, , the timing associated with the completion of FAA certification testing for the Boeing 757-200 combi aircraft already owned by CAM, changes in market demand for our assets and services, and other factors that are contained from time to time in ATSG’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers should carefully review this release and should not place undue reliance on ATSG’s forward-looking statements. These forward-looking statements were based on information, plans and estimates as of the date of this release. ATSG undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

DS Healthcare (DSKX) to Ring NASDAQ Closing Bell

ADVISORY, Dec. 18, 2012 (GLOBE NEWSWIRE) —

What:

DS Healthcare Group, Inc. [DSKX], leader in the development of biotechnology for topical, and nutritional therapies, will visit the NASDAQ MarketSite in Times Square.

DS Healthcare Group, Inc., formerly Divine Skin Inc., began trading on the NASDAQ Capital Markets on December 13, 2012.

In honor of the occasion, Daniel Khesin, CEO, will ring the Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:

Wednesday, December 19, 2012 – 3:45 p.m. to 4:00 p.m. ET

Contact:

Abner Silva
(407) 342-4112
abner@dslaboratories.com

NASDAQ MarketSite:

Jen Knapp
(212) 401-8916
Jennifer.knapp@nasdaqomx.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About DS Healthcare Group, Inc. [DSKX]:

DS Healthcare Group, Inc. leads in the development of biotechnology for topical, and nutritional therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers and salons. Its brands include DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisResearchLabs.com) and Pure Guild (www.ThePureGuild.com).

About NASDAQ OMX Group:

The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade – from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 23 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.99+% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world’s securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook (www.facebook.com/NASDAQ) and Twitter (www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500)

Vanda (VNDA) Announces Positive Phase III Results For Tasimelteon in Non-24-Hour Disorder

— Tasimelteon is shown to entrain the master body clock as measured by melatonin and cortisol circadian rhythms — Tasimelteon is shown to significantly improve clinical symptoms across a number of sleep and wake measures

WASHINGTON, Dec. 18, 2012 /PRNewswire/ — Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced positive results from the SET (Safety and Efficacy of Tasimelteon) Phase III study, evaluating tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24).  Tasimelteon succeeded in the primary endpoint of Entrainment of the melatonin (aMT6s) rhythm as compared to placebo.

Additionally, tasimelteon demonstrated significant improvements across a number of sleep and wake parameters including measures of total sleep time, nap duration, and timing of sleep.  Tasimelteon also showed significant improvements over placebo in the Non-24 Clinical Response Scale (N24CRS) as well as in the Clinical Global Impression of Change (CGI-C), an overall global functioning scale.  These results provide robust evidence of a direct and clinically meaningful benefit to patients with Non-24.

Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception and cannot entrain (reset) their master body clock to the 24-hour day.  Currently there is no approved treatment for Non-24.

“Today’s results confirm tasimelteon as a strong circadian regulator capable of entraining the master body clock in patients with Non-24.  We are particularly impressed and excited by the magnitude and robustness of the direct clinical benefits to patients,” said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda.  “We believe that tasimelteon can be an effective and clinically meaningful treatment for patients suffering with this debilitating disorder.”

“As a person who regularly experiences the debilitating symptoms of Non-24, these findings are important to me and I think they are important to the blind community as a whole, because they give us hope that a potential new treatment approach is on the horizon,” said Melanie Brunson, Executive Director of the American Council of the Blind.

Primary Endpoints

The SET study was an 84 patient randomized, double-masked, placebo-controlled study in patients with Non-24.  The primary endpoints for this study were Entrainment of the melatonin (aMT6s) rhythm to the 24-hour clock and Clinical Response as measured by Entrainment plus a score of greater than or equal to 3 on N24CRS.

Primary Endpoint Results

Table 1

Secondary Endpoints

The SET study also assessed a number of secondary endpoints including Entrainment of cortisol rhythm and a broad range of clinical sleep and wake parameters.  These parameters included improvement in the total nighttime sleep in the worst 25% of nights (LQ-nTST), decrease in the total daytime sleep duration in the worst 25% of days (UQ-dTSD) and midpoint of sleep timing (MoST) which is derived from a combination of the sleep reported for both nighttime and daytime.  CGI-C is a seven-point rating scale of global functioning with lower scores indicating larger improvements.

Secondary Endpoint Results

Table 2

The results of the SET study represent the initial data from the tasimelteon Non-24 Phase III development program and demonstrate the multiple benefits of this novel therapy in treating patients suffering from this rare circadian rhythm disorder.  In the SET study, tasimelteon was demonstrated to be safe and well tolerated.  Vanda expects to report top-line results from the second Phase III study (RESET) for tasimelteon in Non-24 in the first quarter of 2013.  Vanda plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in mid-2013.

“We would like to thank our patients, their advocates, investigators, advisors and colleagues for making this study possible,” said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda.  “We look forward to the successful completion of the Non-24 clinical program.”

Non-24 Scale of Clinical Response (N24CRS)

Tasimelteon Development Program for Non-24

The SET study is the first of four clinical studies conducted as part of Vanda’s Phase III development program for tasimelteon in the treatment of Non-24.  Data from the RESET study, a Phase III study evaluating the maintenance of entrainment effect of tasimelteon, is expected in the first quarter of 2013.  In addition, two safety studies are ongoing to support an NDA filing in the U.S.  The tasimelteon Non-24 development program is the largest conducted to date for any investigational therapy for the treatment of Non-24.

About Non-24-Hour Disorder

Non-24-Hour Disorder (Non-24) is a serious, rare and chronic circadian rhythm disorder that affects a majority of totally blind individuals in the U.S., or between 65,000 and 95,000 people. Tasimelteon has been granted orphan drug designation for the treatment of Non-24 in both the U.S. and the European Union.  Non-24 occurs almost entirely in individuals who lack the light sensitivity necessary to entrain, or synchronize, the master body clock in the brain with the 24-hour day-night cycle.  Most people have a master body clock that naturally runs longer than 24-hours, and light is the primary environmental cue that resets it to 24-hours each day.  Non-24 sufferers have a master body clock that continually delays, putting them to sleep later and later each day, turning night into day and day into night, until the cycle starts all over again.  The sleep condition is highly disruptive, making it difficult to do well in school, hold down a job or maintain relationships.  For more information on Non-24, please visit http://24sleepwake.com/.

About Tasimelteon

Tasimelteon is a circadian regulator in development for the treatment of Non-24. Tasimelteon is a melatonin agonist of the human MT1 and MT2 receptors, with a 2-4 times greater specificity for MT2.  Tasimelteon’s ability to reset the master body clock in the suprachiasmatic nucleus (SCN), located in the hypothalamus, results in the entrainment of the body’s melatonin and cortisol rhythms to align to the 24-hour day-night cycle.  Tasimelteon is currently in development for both Non-24 and Major Depressive Disorder (MDD).

Conference Call
Vanda has scheduled a conference call for today, Tuesday, December 18, 2012 at 9 AM ET to discuss the trial results.  Investors can call 1-800-901-5231 (domestic) and 1-617-786-2961 (international) and use passcode 51793839.  A replay of the call will be available beginning Tuesday, December 18, 2012, at 11:00 AM ET and will be accessible until Tuesday, December 25, 2012, at 12:00 PM ET.  The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers.   The access number is 17591426.

The conference call will be broadcast simultaneously on Vanda’s website, http://www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download and install any necessary software.   The call will also be archived on Vanda’s website for a period of 30 days, through January 17, 2013.

About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit http://www.vandapharma.com.

Company Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

Media Contact:
Kristie Kuhl
Senior Vice President
Makovsky & Company, Inc.
(212)-508-9642
kkuhl@makovsky.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this release are “forward-looking statements” under the securities laws. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “project,” “target,” “goal,” “likely,” “will,” “would,” and “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company’s forward-looking statements include, among others: the inability to reach agreement with the FDA regarding Vanda’s regulatory approval strategy or proposed path to approval for tasimelteon for the treatment of Non-24-Hour Disorder; the failure of Vanda’s clinical trials to demonstrate the safety and/or efficacy of tasimelteon in the treatment of Non-24-Hour Disorder or Major Depressive Disorder; Vanda’s failure to obtain regulatory approval for tasimelteon for the treatment of Non-24-Hour Disorder or to comply with ongoing regulatory requirements; delays in the completion of Vanda’s RESET clinical trial for tasimelteon; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s annual report on Form 10-K for the fiscal year ended December 31, 2011 which is on file with the SEC and available on the SEC’s website at www.sec.gov.  In addition to the risks described above and in Vanda’s annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda’s results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

PokerTek (PTEK) Re-Enters Mexico Gaming Market with PokerPro

MATTHEWS, N.C., Dec. 18, 2012 /PRNewswire/ — PokerTek, Inc. (NASDAQ: PTEK) announced today that it has re-entered the Mexico gaming market. Installations of PokerPro have commenced with games in several locations already live and in play.

“We are excited to see PokerPro back on the floor in Mexico, a market which previously represented over 17% of annualized recurring revenue,” commented Mark Roberson, Chief Executive Officer.

“Installations in Mexico will begin contributing incremental recurring revenue immediately, with 14 tables representing 140 gaming positions already in place and additional sites in planning for the rest of December and early 2013. Our re-entry into the Mexico market represents a significant catalyst for revenue growth and EPS profitability.”

About PokerTek, Inc.:

PokerTek, Inc. (NASDAQ:PTEK) is a licensed gaming company headquartered in Matthews, NC that develops and markets electronic table game solutions for the gaming industry. www.PokerTek.com

Contact:
Mark Roberson
CEO and CFO
PokerTek, Inc.
704.849.0860, x101
investorrelations@pokertek.com

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are made in accordance with the Private Securities Litigation Reform Act of 1995. Our actual results may differ materially from those implied in these forward-looking statements as a result of many factors, including, but not limited to, the impact of global macroeconomic and credit conditions on our business and the business of our suppliers and customers, overall industry environment, customer acceptance of our products, delay in the introduction of new products, further approvals of regulatory authorities, adverse court rulings, production and/or quality control problems, the denial, suspension or revocation of permits or licenses by regulatory or governmental authorities, termination or non-renewal of customer contracts, competitive pressures, and our financial condition, including our ability to maintain sufficient liquidity to operate our business. These and other risks and uncertainties are described in more detail in our most recent annual report on Form 10-K and other reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. We undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by applicable laws, and you are urged to review and consider disclosures that we make in the reports that we file with the Securities and Exchange Commission that discuss other factors germane to our business.

GlobalWise (GWIV) Announces Board Changes

COLUMBUS, OH — (Marketwire) — 12/18/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announced the appointment of Mr. Roy H. Haddix to the Board of Directors of GlobalWise effective December 13, 2012, and the resignation of Ramon M. Shealy from the Board of Directors of GlobalWise effective December 17, 2012. Mr. Haddix has also been appointed to serve as Chairman of the Audit Committee of the Board, and as a member of the Nominating and Corporate Governance Committee of the Board. Mr. Shealy resigned for personal reasons and not as a result of any disagreements.

“We want to thank Mr. Shealy for his unselfish service, guidance and mentorship over the past several years,” stated William “BJ” Santiago, CEO of GlobalWise.

“We’re very pleased to announce that Roy has joined our Board of Directors,” continued Mr. Santiago. “2012 has been a year of significant growth in our channel partner program, client base and revenue. We believe Roy’s knowledge and experience will be of great value as we continue our efforts to rapidly scale our business and add new national and international channel partners in 2013.”

Roy H. Haddix is a senior operations, finance and accounting professional with over 30 years of experience. During his career, he has demonstrated leadership and developed fiscal policies for all levels of corporate organizations. Mr. Haddix has experience in the development of new accounting systems, processes and policies as well as working throughout organizations to increase efficiencies and reduce costs. Mr. Haddix began his accounting career operating and managing his own financial firm with over 700 clients from 1993 through 2001. From 2002 through 2006, Mr. Haddix served as Chief Financial Officer of Buffalo Construction, Inc. (BCI), a $50 million multi-state general contractor. During his tenure as part of the senior management team at BCI, he designed, implemented and managed strategic changes to financial, accounting and operational systems and procedures that enabled a 100% increase in sales while improving net income. From 2006 through 2008, Mr. Haddix was the Tax Manager at TMI, Inc., a $1.25 billion international manufacturing company and subsidiary of Toyota with responsibility for all domestic and international taxes. From 2010 through early 2012 Mr. Haddix served as Chief Financial Officer of Alpharion Capital Partners, Inc., a regional business development and venture capital firm focused on technology related ventures. Throughout his career Mr. Haddix has also been involved with numerous other entrepreneurial and philanthropic ventures.

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Kandi’s (KNDI) First Batch of 300 EVs in Hangzhou City Passed Local DMV Inspection

DragonWave (DRWI) to Announce Third Quarter Fiscal Year 2013 Results

OTTAWA, ONTARIO — (Marketwire) — 12/17/12 — DragonWave Inc. (TSX:DWI)(NASDAQ:DRWI) a leading global supplier of packet microwave radio systems for mobile and access networks, today announced that it will report its third quarter fiscal year 2013 results after the close of markets in North America on January 9, 2013. The company will discuss the results on a conference call and webcast on January 10, 2013 beginning at 8:30 a.m. Eastern Time.

Webcast and Conference Call Details:

Toll-free North America Dial-in: (877) 312-9202

International Dial-in: (408) 774-4000

The live webcast and presentation slides will be available at http://investor.dragonwaveinc.com/events.cfm.

An archive of the webcast will be available at the same link.

About DragonWave

DragonWave® is a leading provider of high-capacity packet microwave solutions that drive next-generation IP networks. DragonWave’s carrier-grade point-to-point packet microwave systems transmit broadband voice, video and data, enabling service providers, government agencies, enterprises and other organizations to meet their increasing bandwidth requirements rapidly and affordably. The principal application of DragonWave’s products is wireless network backhaul. Additional solutions include leased line replacement, last mile fiber extension and enterprise networks. DragonWave’s corporate headquarters is located in Ottawa, Ontario, with sales locations in Europe, Asia, the Middle East and North America. For more information, visit http://www.dragonwaveinc.com.

DragonWave® and Horizon® are registered trademarks of DragonWave Inc.

Forward-Looking Statements

Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements as to DragonWave’s growth opportunities and the potential benefits of, and demand for, DragonWave’s products. These statements are subject to certain assumptions, risks and uncertainties, including our view of the relative position of DragonWave’s products compared to competitive offerings in the industry. Readers are cautioned not to place undue reliance on such statements. DragonWave’s actual results, performance, achievements and developments may differ materially from the results, performance, achievements or developments expressed or implied by such statements. Risk factors that may cause the actual results, performance, achievements or developments of DragonWave to differ materially from the results, performance, achievements or developments expressed or implied by such statements can be found in the public documents filed by DragonWave with U.S. and Canadian securities regulatory authorities. DragonWave assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Contacts:
Nadine Kittle
Marketing Communications
DragonWave Inc.
nkittle@dragonwaveinc.com
613-599-9991 ext 2262

John Lawlor
VP Investor Relations
DragonWave Inc.
jlawlor@dragonwaveinc.com
613-895-7000

Becky Obbema
Interprose Public Relations
(for DragonWave)
Becky.Obbema@interprosepr.com

Metalico (MEA) Enhances Footprint In Cleveland, Rochester

CRANFORD, NJ, December 17, 2012 – Metalico, Inc. (NYSE MKT: MEA) has increased its scrap metal recycling presence in northeastern Ohio and Western New York with a new venture in the Cleveland market and an acquisition in the Greater Rochester area.

In Cleveland, the Company has set up operations in a joint venture at 3018 East 55th Street, the site of a previous scrap yard in the city’s traditional industrial sector.  Managed by industry veteran Joseph Immormino, the strategically located facility, operating as “Metalico JBI Cleveland,” is expected to develop a brisk scrap peddler flow and to service new accounts while supporting Metalico’s existing yards in Akron and Youngstown.

The Company’s Metalico Rochester, Inc. subsidiary has purchased the assets of Bergen Auto Recycling, LLC, including its junk car inventory and real property located at 7652 Clinton Street Road in suburban Bergen, New York.  Metalico plans to significantly expand Bergen Auto’s salvage car buying capabilities and continue its “pick-and-pull” auto parts business while taking advantage of additional access to scrap metal to feed its shredding facility in Buffalo, New York.

Terms and consideration for the two transactions were not disclosed.

“These additions to our network should have an immediate benefit for us,” said Carlos E. Agüero, Metalico’s President and Chief Executive Officer.  “Our full-service scrap yard platforms are already well established in both of these geographic regions and have ample processing capacity to handle additional flow.  Our expansion into these new locations is consistent with Metalico’s growth strategy of penetrating geographically contiguous markets and benefiting from intercompany and operating synergies that are available through consolidation.”

Metalico, Inc. is a holding company with operations in three principal business segments: Ferrous and Non-Ferrous Scrap Metal Recycling, PGM and Minor Metals Recycling, and Fabrication of Lead-Based Products.  The Company operates 29 recycling facilities in New York, Pennsylvania, Ohio, West Virginia, New Jersey, Texas, and Mississippi and four lead fabricating plants in Alabama, Illinois, and California.  Metalico’s common stock is traded on the NYSE MKT under the symbol MEA.

Contact:
Metalico, Inc.
Carlos E. Agüero
Michael J. Drury
info@metalico.com

186 North Avenue East
Cranford, NJ 07016
(908) 497-9610
Fax:  (908) 497-1097
www.metalico.com

Velti (VELT) Shares Up On Jeff Ross Chief Financial Officer Appointment

Velti (NASDAQ: VELT), the leading global provider of mobile marketing and advertising technology and solutions, today announced the appointment of Jeff Ross as the company’s Chief Financial Officer, effective Monday January 7, 2013. With more than 25 years of international finance experience, including at Sybase and PricewaterhouseCoopers, Ross is the fourth senior executive to join Velti’s top ranks in the past six months.

Ross joins Velti from Sybase, where he has been Chief Financial Officer since 2007 and was before Chief Accounting Officer and Corporate Controller, until a $6.8 billion acquisition by SAP. He was responsible for developing, communicating, and monitoring all financial aspects of the company’s overall strategic plan, including controlling, financial planning and analysis, corporate development, tax, treasury, and investor relations. Prior to his promotion to Chief Financial Officer, Ross was Chief Accounting Officer and Corporate Controller of Sybase.

“Jeff is a highly accomplished and respected financial executive in the technology industry and, we are thrilled to have him join our team,” said Alex Moukas, Velti Chief Executive Officer. “His track record of providing strategic leadership and driving balanced growth and cash generation will help us further Velti’s position as the leader in mobile marketing and advertising technology for brands and advertisers. Jeff will lead the initiatives we have already commenced reviewing our organization and customer base, remaining focused on cash generation, ongoing reduction of operating and capital expenses and growth in our key markets.”

“With the recent additions of Jeff as CFO, Harry Patz as Chief Revenue Officer, Jason Hoffman as SVP Product Management and Jesper Helt as SVP Human Resources, we are well positioned as we start the next stage of our development” added Moukas.

“Velti is playing a leading role in helping to shape the rapidly evolving mobile marketing and advertising industry, and is uniquely positioned with its extensive global presence and potential,” said Ross. “I am very excited to join the Velti team and lead the company’s financial operations, with a focus on cash flow generation and growth in key markets.”

Wilson Cheung, Velti’s current Chief Financial Officer, will remain with Velti and transition into a new role in its fast-growing Asian markets. “As we welcome Jeff to Velti, we also want to thank Wilson for all of the effort that he provided in the last 3 years,” said Moukas. “We look forward to his continued contributions and thank him for his commitment to a smooth transition to Jeff,” concluded Moukas.

GenVec (GNVC) Single Administration of Vaccine Provides Protective Immunity Against HSV

Single Administration of GenVec’s Vaccine Provides Protective Immunity Against HSV in Pre-clinical Animal Models

GAITHERSBURG, Md., Dec. 17, 2012 /PRNewswire/ — GenVec, Inc. (NASDAQ:GNVC) announced today that data were presented on its HSV vaccine program at the Keystone Symposia meeting on Immunological Mechanisms of Vaccination, which is taking place in Ottawa, Ontario from December 13 to December 18, 2012.

The company disclosed that a single administration of its genetic vaccine was effective against HSV2 in two industry-accepted HSV disease models.  Specifically, immunization was shown to reduce viral shedding, and the recurrence and severity of lesions.

GenVec’s HSV vaccine candidate generated effective immune responses in animal models; and is composed of two novel antigens, as well as a proprietary, non-human adenoviral vector.

“We have substantial evidence that HSV infection can be controlled by inducing an appropriate T-cell response,” said Dr. Lisa Wei, Senior Director of Research and head of GenVec’s HSV program. “The data presented at this symposium demonstrate the progress we are making towards the goal of creating a vaccine for treatment and potentially prophylaxis of HSV infection.”

Research reported in this release was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under grant number 5R43AIO77147-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Herpes Simplex Virus (HSV)

In the United States, approximately 40 million people are currently infected with HSV2, which is  responsible for most cases of genital herpes, and 1.6 million new infections occur each year. About 25% of those infected with the virus suffer clinical symptoms. Even higher infection rates are evident in developing countries. HSV2 infection is associated with increased HIV infection and transmission; and further complications of HSV are also often seen in those co-infected with HIV. HSV infections are permanent, and result in periodic virus shedding. Although antiviral regimens have become a standard of care, their inconvenience, cumulative cost and potential for drug resistance further underscore the need for safe, new approaches to reduce HSV lesions, virus shedding, and transmission. Estimated costs of treating HSV in the United States alone are close to $1 billion, primarily for drugs and outpatient medical care. There is no FDA-approved vaccine for HSV.

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company’s filings with the U.S. Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the Company’s collaborations, including with Novartis and Merial, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec’s product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec’s proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; currently unanticipated expenses, and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec’s business, financial conditions and results of operations, are contained in GenVec’s filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

Wireless Ronin (RNIN) Completion of One-for-Five Reverse Stock Split

MINNEAPOLIS, MN — (Marketwire) — 12/17/12 — Wireless Ronin Technologies, Inc. (NASDAQ: RNIN) today announced that its one-for-five reverse stock split was completed effective on the close of business on December 14, 2012. Trading of the Company’s common stock on The NASDAQ Capital Market will begin on a split-adjusted basis at the open of trading on December 17, 2012.

On November 29, 2012, the Company’s Board of Directors approved a one-for-five share combination of its common stock, also known as a reverse stock split, to be effective at 5:00 p.m. ET on December 14, 2012. The Company filed an amendment to its Articles of Incorporation to effect the reverse stock split.

The reverse stock split is intended to enable the per share trading price of the Company’s common stock to increase to satisfy the minimum bid price requirement for continued listing set forth in NASDAQ Listing Rule 5810(b).

As a result of the reverse stock split, every five shares of the Company’s common stock that were issued and outstanding as of the effective time were automatically combined into one issued and outstanding share without any change in the par value of such shares, and the number of authorized but unissued shares of the Company’s common stock was proportionally reduced. A proportionate adjustment also was made to the Company’s outstanding derivative securities. To reflect the reverse stock split, NASDAQ will append the fifth character “D” to the ticker symbol of the Company’s common stock for 20 business days.

No fractional shares of common stock will be issued as a result of the reverse stock split. Shareholders of record who would otherwise be entitled to fractional shares will receive cash in lieu of fractional shares.

Following the reverse stock split, the Company expects to have approximately 4,998,014 shares of common stock outstanding. The CUSIP number for the post-split shares will be 97652A 302.

About Wireless Ronin Technologies, Inc.
Wireless Ronin Technologies, Inc. (WRT) (NASDAQ: RNIN) (www.wirelessronin.com), is a marketing technologies company with leading expertise in current and emerging digital media solutions, including signage, interactive kiosks, mobile, social media and web, that enable clients to transform how they engage with their customers. WRT provides marketing technology solutions and services to clients, helping increase revenue and improve operating efficiencies to execute marketing initiatives. Since launching RoninCast® digital signage software in 2003, WRT has led the digital signage industry by bringing leading edge technology, services and support to its clients. WRT offers an array of services to support its clients’ marketing technology needs including consulting, creative development, project management, installation, training, and support and hosting. The company’s common stock trades on the NASDAQ Capital Market under the symbol “RNIN.” Follow us on Twitter (https://twitter.com/wirelessronin) and Pinterest (http://pinterest.com/rnin/) and like us on Facebook (https://www.facebook.com/wirelessronin).

Forward-Looking Statements
This release contains certain forward-looking statements of expected future developments, as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management’s expectations regarding continued listing on NASDAQ and other matters and are based on currently available data; however, actual results are subject to future risks and uncertainties, which could materially affect actual performance. Risks and uncertainties that could affect such performance include, but are not limited to, the following: estimates of future expenses, revenue and profitability; the pace at which the company completes installations and recognizes revenue; trends affecting financial condition and results of operations; ability to convert proposals into customer orders; the ability of customers to pay for products and services; the revenue recognition impact of changing customer requirements; customer cancellations; the availability and terms of additional capital; ability to develop new products; dependence on key suppliers, manufacturers and strategic partners; industry trends and the competitive environment; and the impact of losing one or more senior executives or failing to attract additional key personnel. These and other risk factors are discussed in detail in the risk factors section of the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 21, 2012.

Company Contact:
Darin P. McAreavey
Senior Vice President and Chief Financial Officer
Email Contact
952-564-3525

Investor Relations Contact:
Matt Glover or Michael Koehler
Liolios Group, Inc.
Email Contact

GreenHunter (GRH) Launches Modular Above-Ground Water Storage System

Proprietary MAG Tank™ Design Employs Patent Pending Standardized Interlocking Steel Panels Allowing Oil and Gas Operators to Customize Tank Footprint and Capacity

GreenHunter Energy, Inc. (NYSE MKT: GRH) (NYSE MKT: GRH.PRC), a diversified water resource, waste management and environmental services company specializing in the unconventional oil and natural gas shale resource plays, announced today that its wholly owned subsidiary, GreenHunter Water, LLC, has released its next-generation modular above-ground water storage tank system for general availability to the oil and gas industry. The fabrication of panels for the first MAG Tank unit has been completed with deployment slated for the last week in December in St. Mary Parish, Louisiana.

The Patent Pending MAG Tank™ design provides operators with a customizable steel tank footprint in unlimited capacity and shape configurations above 10,900 barrels. The MAG Tank™ is GreenHunter Water’s response to requests from our existing customers for a large capacity temporary water storage system that can be installed on a variety of well pads – especially those in challenging terrain as found in the states of Ohio, West Virginia, Pennsylvania and Kentucky in the Appalachian region. MAG Tank is an innovative substitute to the industry-standard circular above ground tank systems.

The MAG Tank™ significantly reduces truck traffic and environmental disturbance when compared to traditional frac tank and earthen impoundment alternatives. The tank’s robust steel standard panel wall units enable quick assembly and disassembly and a disposable impermeable liner and geotextile substrate provide fluid containment and a puncture resistant ground covering. After pad site preparation, a MAG Tank is typically installed in one to two days. The MAG Tank design exceeds current safety and engineering standards.

MANAGEMENT COMMENTS

Commenting on this new product line, Mr. Jonathan D. Hoopes, GreenHunter Energy’s President and COO, stated, “For oil and gas operators who are looking to reduce their cost, minimize truck traffic, increase safety, improve logistics and reduce environmental impact, the MAG Tank System is the solution. We have worked extremely hard over the past year to design a product that met all the requirements of our customers and at a manufacturing cost that insures our margin objectives. We are anxious to offer this uniquely designed system to our oilfield customers and anticipate this product to be significantly accretive to our projected earnings in fiscal 2013.”

About GreenHunter Water, LLC (a wholly owned subsidiary of GreenHunter Energy, Inc.)

GreenHunter Water, LLC provides Total Water Management Solutions™ in the oilfield. An understanding that there is no single solution to E&P fluids management shapes GreenHunter’s technology-agnostic approach to services. In addition to licensing of and joint ventures with manufacturers of mobile water treatment systems (Frac-Cycle™), GreenHunter Water is expanding capacity of salt water disposal facilities, next-generation modular above-ground storage tanks (MAG Tank™), advanced hauling and fresh water logistics services—including 21st Century tracking technologies (RAMCAT™) that allow Shale producers to optimize the efficiency of their water resource management and planning while complying with emerging regulations and reducing cost.

Additional information about GreenHunter Water may be found at www.GreenHunterWater.com.

Forward-Looking Statements

Any statements in this press release about future expectations and prospects for GreenHunter Energy and its business and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will,” “could,” “should,” “budget,” “continue,” and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in the press release include, without limitation forecasts of growth, revenues, adjusted EBITDA and SWD well and rolling stock expansion. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the substantial capital expenditures required to fund its operations, the ability of the Company to fund and implement its business plan, government regulation and competition. Additional risks and uncertainties are set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as well as the Company’s other reports filed with the United States Securities and Exchange Commission and are available at http://www.sec.gov/ as well as the Company’s website at http://greenhunterenergy.com/. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. All forward-looking statements are qualified in their entirety by this cautionary statement. GreenHunter Energy undertakes no obligation to update these forward-looking statements in the future.

Intelligent Systems (INS) Announces Third Quarter 2012 Results

Restates Prior Year to Conform to Current Accounting Standard

NORCROSS, Ga., Nov. 14, 2012 (GLOBE NEWSWIRE) — Intelligent Systems Corporation (NYSE Amex:INS) (www.intelsys.com) announced today its financial results for the three and nine month periods ended September 30, 2012. The comparative results for the 2011 periods have been restated to correct a misinterpretation of an accounting standard related to allocation of income/losses of noncontrolling common stock interests in a subsidiary, as explained in more detail below under the heading Restatement of 2011 Results.

For the three month period ended September 30, 2012, Intelligent Systems reported total revenue of $4,075,000 compared to $4,930,000 in the same quarter of 2011. The net income attributable to Intelligent Systems was $230,000 ($0.03 per basic and diluted share) compared to net income attributable to Intelligent Systems of $567,000 ($0.06 per basic and diluted share) in the third quarter of 2011.

For the nine month period ended September 30, 2012, total revenue was $12,201,000 compared to revenue of $12,631,000 in the comparable period of 2011. Net income attributable to Intelligent Systems was $225,000 ($0.03 per basic and diluted share) in the nine month period ended September 30, 2012 compared to net income of $1,158,000 ($0.13 per basic and diluted share) in the comparable period in 2011.

The year-to-date results are not directly comparable to prior year results due to non-recurring income of $450,000 that is included as Other Income in the year-to-date period ended September 30, 2011. As previously reported, the Company’s ChemFree subsidiary entered into a settlement agreement in May 2011 related to previously imposed court sanctions against a third party. The matter was resolved in ChemFree’s favor by payment to ChemFree of $450,000 for reimbursement of certain legal expenses.

J. Leland Strange, President and Chief Executive Officer, stated, “Our ChemFree subsidiary had another strong, profitable quarter, with revenue growth of nine percent in both the third quarter and year-to-date periods, compared to the same periods in 2011. The results were fueled by stronger sales and lease revenue from ChemFree’s SmartWasher® bio-remediating parts washers in the domestic U.S. market.

“Our CoreCard subsidiary results were consistent with those reported for the first two quarters of 2012. Revenue from professional services and maintenance activities increased in both the quarter and year-to-date periods of 2012 compared to the same periods in 2011. However, license revenue from new software contracts (which is classified as product revenue in our income statement) was lower in both the quarter and year-to-date periods of 2012 than in the same periods in 2011. We continue to invest substantial resources to develop our processing services business and enhance our financial transaction software solutions for prepaid, fleet and private label cards, which has had a major impact on our reported financial results.”

As we have frequently cautioned, results may vary from quarter-to-quarter due in part to the timing of CoreCard software contract revenue recognition. Generally, we defer all revenue associated with contract milestone payments on new CoreCard customer implementations until the contract is completed, which may frequently be affected by factors outside of our control.

Restatement of 2011 Results. On November 8, 2012, the Company determined that it had misinterpreted an accounting standard adopted in 2009 related to allocation of income/losses of noncontrolling common stock interests in a subsidiary. We have not been applying the guidance correctly in all respects because we have not been attributing to the noncontrolling interest (held by common shareholders of our CoreCord Software subsidiary) its share of the losses or income of the subsidiary and have not been disclosing such attributed amounts on the face of the consolidated statements of operations. Accordingly, we have restated the consolidated statements of operations for the quarter and year-to-date periods ended September 30, 2011 and the stockholders’ equity section of the consolidated balance sheets as of December 31, 2011 to comply with the standard. The restated prior year results now show on the face of the statement of operations, below the previously reported net income/loss figure, the allocation of net income/loss attributable to the noncontrolling interest and to Intelligent Systems Corporation and also the revised equity component of the balance sheet to reflect the allocation of cumulative losses to the noncontrolling interest. The restatement did not change the previously reported revenue, costs, expenses, net income/loss, cash flow, assets, liabilities or total shareholders’ equity. Earnings per share changed from the previously reported numbers (declining by $0.02 per share and increasing by $0.02 for the three and nine month periods ended September 30, 2011, respectively) because earnings per share is now calculated on net income/loss allocable to Intelligent Systems, rather than total net income/loss. Also, after restatement, shareholders’ equity attributable to Intelligent Systems at December 31, 2011 increased to $7,150,000 as compared to $5,531,000 previously reported and the noncontrolling shareholders’ equity interest became a deficit of $103,000 compared to equity of $1,516,000 as previously reported. Total stockholders’ equity was unchanged at $7,047,000.

The Company is filing a Form 8-K today with further details about the restatement of prior period financial statements and will file its Form 10-Q for the quarter ended September 30, 2012 as scheduled today, including the restated amounts and explanation thereof.

About Intelligent Systems Corporation

For over thirty years, Intelligent Systems Corporation has identified, created, operated and grown early stage technology companies. The Company has operations and investments in the information technology and industrial products industries. The Company’s principal majority-owned subsidiaries are CoreCard Software, Inc. (www.corecard.com), a provider of licensed software for managing accounts receivables, prepaid cards, private label revolving credit, debit and credit cards, fleet cards, consumer loans as well as processing services and ChemFree Corporation (www.chemfree.com), a leader in bioremediating parts washer equipment and supplies. Further information is available on our website at www.intelsys.com or by calling us at 770-381-2900.

In addition to historical information, this news release may contain forward-looking statements relating to Intelligent Systems Corporation and its subsidiary and affiliated companies. These statements include all statements that are not statements of historical fact regarding the intent, belief or expectations of Intelligent Systems Corporation and its management with respect to, among other things, results of operations, product plans, and financial condition. The words “may,” “will,” “anticipate,” “believe,” “intend,” “expect,” “estimate,” “plan,” “strategy” and similar expressions are intended to identify forward-looking statements. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. The Company does not undertake to update or revise any forward-looking statements whether as a result of new developments or otherwise, except as required by law. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are instability in the financial markets, delays in product development, undetected software errors, competitive pressures, changes in customers’ requirements or financial condition, market acceptance of products and services, changes in the performance, financial condition or valuation of affiliate companies, the risks associated with investments in privately-held early stage companies and further declines in general economic and financial market conditions, particularly those that cause businesses to delay or cancel purchase decisions.

CONTACT: For further information, call
         Bonnie Herron, 770-564-5504
         or email to bherron@intelsys.com

SiriusXM’s (SIRI) Not Fade Away Town Hall

SiriusXM’s Town Hall to offer SiriusXM listeners the chance to participate in Q&A with the creator and stars of the “The Sopranos” about the new film “Not Fade Away” in the SiriusXM studios Town Hall to be moderated by Terence Winter, creator of “Boardwalk Empire” and writer for “The Sopranos”

NEW YORK, Dec. 14, 2012 /PRNewswire/ — Sirius XM Radio (NASDAQ: SIRI) announced today that the creator and stars of The Sopranos, David Chase, James Gandolfini and Steven Van Zandt, will sit down for a Q&A session with a select group of SiriusXM listeners about their new film Not Fade Away from Paramount Vantage at the SiriusXM studios in New York City.

(Logo: http://photos.prnewswire.com/prnh/20101014/NY82093LOGO)

“SiriusXM’s Not Fade Away Town Hall” with David Chase, James Gandolfini and Steven Van Zandt, which will take place on Monday, December 17, will air on Underground Garage, channel 21, on Thursday, December 20 at 7:00 pm ET.  For rebroadcast times please visit www.siriusxm.com/townhall.

Moderated by Terence Winter, the Town Hall will feature Not Fade Away’s writer and director David Chase, actor James Gandolfini and the film’s executive producer and musical supervisor Steven Van Zandt answering fan questions about their careers, HBO’s The Sopranos, and their new film, which will be released in theaters nationwide on December 21.

“SiriusXM’s Not Fade Away Town Hall” with David Chase, James Gandolfini, and Steven Van Zandt is part of SiriusXM’s “Town Hall” series featuring intimate gatherings with iconic entertainers and figures sitting down with a studio audience of SiriusXM listeners. Previous SiriusXM “Town Hall” specials have featured Bruce Springsteen, Cardinal Timothy Dolan, Carol Burnett, Tom Petty, KISS, Coldplay, Ringo Starr, Roger Waters, the surviving members of Nirvana, Renee Fleming, Gregg Allman, Usher, Duke basketball coach Mike Krzyzewski and Tony Hawk.

“David, James and Steven worked together to make television history with The Sopranos and now they’ve collaborated on Not Fade Away, a movie whose music will be as interesting as its storyline,” said Scott Greenstein, President and Chief Content Officer, SiriusXM. “We are excited to have them in a rare setting together in our studios in front of lucky fans who can ask them about the effect their work has had on a generation of viewers, and how their new film will expose a new generation to the revolution that transformed pop and rock music in the ’60s.”

After the broadcast, “SiriusXM’s Not Fade Away Town Hall” with David Chase, James Gandolfini and Steven Van Zandt will be available on SiriusXM On Demand for subscribers listening via the SiriusXM Internet Radio App for smartphones and other mobile devices or online at siriusxm.com. Visit www.siriusxm.com/ondemand for more information on SiriusXM On Demand.

For more information on SiriusXM, please visit www.siriusxm.com.

About Sirius XM Radio
Sirius XM Radio Inc. is the world’s largest radio broadcaster measured by revenue and has 23.4 million subscribers.  SiriusXM creates and broadcasts commercial-free music; premier sports talk and live events; comedy; news; exclusive talk and entertainment; and the most comprehensive Latin music, sports and talk programming in radio. SiriusXM is available in vehicles from every major car company in the U.S., from retailers nationwide, and online at siriusxm.com. SiriusXM programming is also available through the SiriusXM Internet Radio App for Android, Apple, and BlackBerry smartphones and other connected devices. SiriusXM also holds a minority interest in SiriusXM Canada which has more than 2 million subscribers.

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.  Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control.  Actual results may differ materially from the results anticipated in these forward-looking statements.

The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements:  our competitive position versus other forms of audio entertainment; our dependence upon automakers; general economic conditions; failure of our satellites, which, in most cases, are not insured; our ability to attract and retain subscribers at a profitable level; royalties we pay for music rights; the unfavorable outcome of pending or future litigation; failure of third parties to perform; and our substantial indebtedness.  Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our Annual Report on Form 10-K for the year ended December 31, 2011, which is filed with the Securities and Exchange Commission (the “SEC”) and available at the SEC’s Internet site (http://www.sec.gov).  The information set forth herein speaks only as of the date hereof, and we disclaim any intention or obligation to update any forward looking statements as a result of developments occurring after the date of this communication.

Follow SiriusXM on Twitter or  like the SiriusXM page on Facebook.

P-SIRI

Media Contact:
Samantha Bowman
SiriusXM
212 901 6644
samantha.bowman@siriusxm.com

LifeVantage (LFVN) Announces Shares Repurchase Program

Company Authorized Repurchase of Up to $5 Million in Shares of Its Common Stock

SALT LAKE CITY, Dec. 14, 2012 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, including its patented dietary supplement Protandim^®, the Nrf2 Synergizer^®, announced today that its Board of Directors approved a share repurchase program that authorizes the Company to utilize up to $5 million to purchase shares of its common stock. Any such repurchases will be made out of existing cash or free cash flow from continuing operations.

The repurchase program permits LifeVantage to purchase shares from time to time through a variety of methods, including in the open market, through privately negotiated transactions or other means as determined by the company’s management, in accordance with applicable securities laws. As part of the repurchase program, the Company expects that it will enter into a pre-arranged stock repurchase plan which would operate in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934. Accordingly, transactions, if any, under the pre-arranged repurchase plan would be effected in accordance with the terms of the stock repurchase plan, including specified price, volume and timing conditions.

“Given the underlying strength of our business and the recent turbulence in the equity markets, we believe the stock buy-back program is in the best interests of our stockholders,” Douglas C. Robinson, LifeVantage President and CEO, stated. “We intend to implement this buyback program while maintaining sufficient resources to continue to improve our balance sheet and invest in future expansion opportunities.”

The LifeVantage Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11617

Forward Looking Statements

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believe,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our future prospects and our expectation that we will repurchase shares. Such forward-looking statements are not guarantees of performance and the Company’s actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the potential failure or unintended negative consequences of the implementation of the Company’s network marketing sales channel; the Company’s ability to retain independent distributors or to attract new independent distributors on an ongoing basis; the potential for third party and governmental actions involving the Company’s network marketing sales channel; the potential for product liability claims against the Company; the risk that government regulators and regulations could adversely affect the Company’s business; future laws or regulations may hinder or prohibit the production or sale of the Company’s existing product and any future products; unfavorable publicity could materially hurt the Company’s business; and the Company’s ability to protect its intellectual property rights and the value of its product. These and other risk factors are discussed in greater detail in the Company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption “Risk Factors,” and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

CONTACT: Investor Relations Contact:
         Cindy England (801) 432-9036
         Director of Investor Relations
         -or-
         John Mills (310) 954-1105
         Senior Managing Director, ICR, LLC

B.O.S (BOSC) Announces 1-for-4 Reverse Split of Ordinary Shares

RISHON LEZION, Israel, Dec. 14, 2012 (GLOBE NEWSWIRE) — The Company hereby announces that the reverse share split previously announced by the Company on October 31, 2012, shall become effective on December 14, 2012. Pursuant to the reverse split, each 4 Ordinary Shares, NIS 20.00 nominal value per share, will be converted into one Ordinary Share, NIS 80.00 nominal value per share. No fractional shares will be issued as a result of the reverse-split. Instead, all fractional shares will be rounded up to the next higher whole number of shares.

As of December 13, 2012, there were 4,472,298 Ordinary Shares outstanding and after the reverse split there will be 1,118,081 Ordinary Shares outstanding. The exchange agent for the reverse split is American Stock Transfer & Trust Company, whose address is 6201 15^th Avenue, Brooklyn, N.Y. 11219 (tel:  (718) 921- 8317 or (877) 248-6417). Once effective, the post-split shares will trade on the Nasdaq Capital Market under the same symbol “BOSC”.

About BOS

B.O.S. Better Online Solutions Ltd. (Nasdaq:BOSC) is a leading provider of RFID and Supply Chain solutions to global enterprises, that help customers worldwide improve the efficiency of their logistics and organizational monitoring and control. BOS’ RFID and Mobile division offers both turnkey integration services as well as stand-alone products, including best-of-breed RFID and AIDC hardware and communications equipment, BOS middleware, and industry-specific software applications. BOS’ Supply Chain division provides electronic components consolidation services to the aerospace, defense, medical and telecommunications industries.

For more information, please visit:www.boscorporate.com

CONTACT: For more information:
         Eyal Cohen
         CFO
         +972-542525925

U.S. Geothermal’s (HTM) Neal Hot Springs Project Update

BOISE, IDAHO — (Marketwire) — 12/13/12 — U.S. Geothermal Inc. (TSX:GTH)(NYSE MKT:HTM), a leading renewable energy company focused on the development, production and sale of electricity from geothermal energy, provides this update on the Neal Hot Springs project located near Vale, Oregon.

The three module plant is operating and currently delivering 23.0 net megawatts (“MW”) to our customer, Idaho Power Company, with the following status of each module unit:

--  Unit 1 is currently online and operational with gross generation of 11.0
    MW;
--  Unit 2 is also online and operational with gross generation of 10.4 MW;
    and,
--  Unit 3 currently online and was recently synchronized to the grid. Gross
    generation from Unit 3 is 8.7 MW operating in sub critical mode.

The three modules are still undergoing various mechanical and control system adjustments, tests and modifications to meet overall design criteria. The project contractor is expected to complete work during the first quarter of 2013.

Please visit our Website at: www.usgeothermal.com

About U.S. Geothermal Inc.:

U.S. Geothermal Inc. is a leading renewable energy company focused on the development, production and sale of electricity from geothermal energy and is operating geothermal power projects at Raft River, Idaho, San Emidio, Nevada and Neal Hot Springs, Oregon. The company is developing El Ceibillo, an advanced stage, steam geothermal prospect located within a 24,710 acre (100sq km) energy rights concession area located 8.5 miles (14 km) from Guatemala City, the largest city in Central America.

The information provided in this news release may contain forward-looking statements within the definition of the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995. These statements are based on U.S. Geothermal Inc.’s current expectations and beliefs and are subject to a number of risks and uncertainties that can cause actual results to differ materially from those described, including but not limited to, the results from the start up activities and ongoing production potential of Neal Hot Springs. Readers are cautioned to review the risk factors identified by the company in its filings with Canadian and US securities agencies. Forward-looking statements are based on management’s expectations, beliefs and opinions on the date the statements are made. U.S. Geothermal Inc. assumes no obligation to update forward-looking statements if management’s expectations, beliefs, or opinions, or other factors, should change.

The NYSE MKT and the TSX do not accept responsibility for the adequacy of this release.

Contacts:
U.S. Geothermal Inc.
Saf Dhillon
Investor Relations
866-687-7059
208-424-1030 (FAX)
saf@usgeothermal.com

SoundBite (SDBT) Announces Special Dividend to Stockholders Payable in December 2012

BEDFORD, Mass., Dec. 13, 2012 (GLOBE NEWSWIRE) — SoundBite Communications (Nasdaq:SDBT), a provider of customer experience management solutions, today announced that its Board of Directors has declared a special, one-time cash dividend of $0.50 per share payable on or before December 31, 2012 to stockholders of record at the close of business on December 23, 2012. The total amount of the special dividend payment will be approximately $8.2 million.

“SoundBite has a solid balance sheet, with approximately $24 million in cash at the end of the third quarter and no long term debt,” said Jim Milton, President and Chief Executive Officer. “We have preserved our cash while funding the acquisition of three mobile companies, executing on a stock buyback program, and investing in transforming the company into a strong position within two growth markets – mobile marketing and the hosted contact center.  SoundBite is on a path towards achieving sustained profitability and has decided to return some of the cash to our stockholders in the form of a fifty-cent dividend.”

Milton continued, “We have made great progress recently in improving our position on the litigation and regulatory front with the favorable declaratory ruling by the FCC on our petition.  Based on our solid positioning in the mobile marketing and hosted contact center markets, we are confident that we can grow organically and will not need this cash for future acquisitions.  We believe that this special dividend will provide stockholders with additional value and appropriately reward them for their continued support.”

SoundBite intends to continue to invest in its mobile marketing and hosted contact center market opportunities, as well as capital expenditures to support platform and infrastructure expansion.

As a result of the special dividend, the exercise prices of some outstanding stock awards will decrease, and the number of shares subject to certain stock awards may increase, pursuant to the existing terms of SoundBite’s equity incentive plan. SoundBite will not be able to determine the extent of those adjustments until early January 2013.

About SoundBite Communications

SoundBite Communications is a customer experience management company with deep expertise in delivering cloud-based mobile marketing, proactive customer care, and collections/payments solutions. More than 450 global end-clients, including nearly 50 Fortune 500 companies, leverage SoundBite’s proactive multi-channel communications and preference management platforms to power 2.5 billion personalized and compliant customer interactions annually across the full consumer lifecycle. Visit SoundBite.com and follow SoundBite on Twitter for more information. SoundBite is a registered service mark of SoundBite Communications, Inc.

The SoundBite Communications, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4393

CONTACT: IR & Media Contact:
         Lynn Ricci
         SoundBite Communications
         781-897-2696
         lricci@soundbite.com
         www.SoundBite.com

Oncolytics (ONCY) Positive Top Line REOLYSIN® Data Head and Neck Cancer

CALGARY, Dec. 13, 2012 /PRNewswire/ – Oncolytics Biotech Inc. (“Oncolytics” or the “Company”) (TSX: ONC) (NASDAQ: ONCY) today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018).

The endpoint examines initial percentage tumour changes between the pre-treatment and first post-treatment scans (typically performed at six weeks post-first treatment) of all patients enrolled in the study. The analysis was designed to assess early differences in response between loco-regional tumours and metastatic tumours, as classified and observed by the investigators. This is the first, and to this point only, endpoint to be un-blinded for this study.

The first analysis compared the relative percentages of patients in the test and control arms with tumours that had either stabilized or exhibited shrinkage. For the purposes of this endpoint, the definition of tumour stabilization was restricted to zero percent growth only. Of the 105 total patients with evaluable metastatic tumours, 86 percent (n=50) of those in the test arm of the study exhibited tumour stabilization or shrinkage, compared with 67 percent of patients (n=55) in the control arm. This was statistically significant, with a p-value of 0.025.

The second analysis examined the magnitude of tumour response on a per patient basis using a comparison of percentage tumour shrinkage at six weeks in each patient with evaluable metastatic tumours. This analysis showed that REOLYSIN in combination with carboplatin and paclitaxel was statistically significantly better than carboplatin and paclitaxel alone at stabilizing or shrinking metastatic tumours, yielding a p-value of 0.03.

At the six week point, there is a numeric trend in favour of the test group towards differing activity between the test and control groups in patients with loco-regional tumours.

In an intragroup analysis of the test arm, an improvement in the percentage of patients’ metastatic tumours over loco-regional tumours was noted (p=0.083) and an improvement of magnitude of response in metastatic tumours over loco-regional tumours was also noted (p=0.13). By contrast, in an intragroup analysis of the control arm, no statistical differences were noted between the responses of patients with evaluable metastatic tumours and patients with evaluable loco-regional tumours.

“To the best of our knowledge, this is the first successful double-blinded randomized data from a clinical study using an intravenously-administered oncolytic virus. We are delighted to have obtained statistically significant data for REOLYSIN in a randomized clinical setting,” said Dr. Brad Thompson, President and CEO of Oncolytics. “We continue to await the data for the other endpoints of this study, to which all parties still remain blinded at this point.”

Conference Call Details
Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast on Thursday, December 13^th, 2012 at 6:00 a.m. MT (8:00 a.m. ET) to discuss in more depth the Company’s Phase III study in head and neck cancers. To access the conference call by telephone, dial 1-647-427-7450 or 1-888-231-8191. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/detail/1087657/1184933 or through the Company’s website at www.oncolyticsbiotech.com/presentations. Please connect at least 10 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at www.oncolyticsbiotech.com/presentations and will also be available by telephone through December 20^th, 2012. To access the telephone replay, dial 1-416-849-0833 or 1-855-859-2056 and enter reservation number 81080621 followed by the number sign. The Company also intends to post the prepared remarks from the call to its corporate website following the call.

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics’ clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN^®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in the future, including such things as, the Company’s expectations related to the Phase III head and neck cancers trial of REOLYSIN in combination with carboplatin and paclitaxel, and the Company’s belief as to the potential of REOLYSIN as a cancer therapeutic, and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statement and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.

ATC Venture Group (ATC) to Return to the OTC Market

ATC Venture Group Inc. (the “Company”) (NYSE MKT: ATC) announced that it will be returning its listing to the OTC Markets (the”OTC”) from the NYSE MKT (the “Exchange”). The Company’s common stock had previously been traded on the OTC.

The Company expects that the stock will begin trading under a new 4-character ticker symbol on the OTC commencing on Monday, December 17, 2012. Investors will be able to view the Real Time Level II stock quotes for at http://www.otcmarkets.com.

“We believe that the transition to the OTC will provide existing and new shareholders a quality marketplace to trade our stock,” said Robert Davis, Chairman and CEO of the Company. “Furthermore, we believe that the turnaround process that we have been in for the past few years has led to a deeply depressed stock price, and a change to the new market may provide a fresh opportunity for new participants to become aware of us. In addition, there are substantial cost savings to the Company from this change.”

As previously disclosed, on October 5, 2012, the Company received notice from the NYSE MKT indicating that the Company no longer complied with the Exchange’s continued listing standards because the aggregate market value of its public float was less than $1.0 million for 90 consecutive days as set forth in Section 1003(b)(i)(C) of the Exchange’s Company Guide, because it had yet to file its Form 10-Q for the quarter ended June 30, 2012 as set forth in Sections 134 and 1101 of the Company Guide, and because of the low price of the Company’s common stock as set forth in Section 1003(f)(v) of the Company Guide. As a result, the Exchange staff recommended that the Company’s common stock be delisted. The Company appealed their determination.

On December 6, 2012, the Company’s appeal was heard by the Listing Qualifications Panel of the Exchange. On December 10, 2012, the Company received a letter from the Listing Qualifications Panel of the Exchange affirming the staff decision to delist the Company’s common stock.

Mr. Davis said, “After reflecting on the Company’s alternatives to the NYSE MKT, we are confident that our shareholders will be well served by the lower cost platform of the OTC, while we continue to work to create shareholder value. We believe this transition to the OTC will be a positive transition for existing and new shareholders to benefit from their involvement with our business.”

About ATC Venture Group Inc.:

ATC Venture Group is the parent company to Simonsen Iron Works Inc., an Iowa-based fabricator, powder coat painter, and assembler of metal-based products since 1906. It previously owned Cycle Country Accessories, which for over 30 years was the industry leading designer, manufacturer and marketer of snow plows and other accessories for the ATV/UTV Powersports industry, as well as previously owned several other Powersports and Golf industry product businesses.

TORM (TRMD) Regains Compliance With NASDAQ Listing Rules

COPENHAGEN, Denmark, Dec. 12, 2012 (GLOBE NEWSWIRE) — TORM A/S (Nasdaq:TRMD) has received confirmation from NASDAQ Listing Qualifications that the Company’s American Depository Receipts (ADRs) have closed (bid) at USD 1.00 per ADR or greater for ten consecutive trading days. Accordingly, the Company has regained compliance with the NASDAQ Stock Market listing rules.

Contact TORM

A/SJacob Meldgaard, CEO, tel.: +45 3917 9200
Roland M. Andersen, CFO, tel.: +45 3917 9200
C. Soegaard-Christensen, IR, tel.: +45 3076 1288

Tuborg Havnevej 18
DK-2900 Hellerup, Denmark
Tel.: +45 3917 9200 / Fax: +45 3917 9393
www.torm.com

About TORM

TORM is one of the world’s leading carriers of refined oil products as well as a significant player in the dry bulk market. The Company operates a fleet of approximately 110 modern vessels in cooperation with other respected shipping companies sharing TORM’s commitment to safety, environmental responsibility and customer service.
TORM was founded in 1889. The Company conducts business worldwide and is headquartered in Copenhagen, Denmark. TORM’s shares are listed on NASDAQ OMX Copenhagen (ticker: TORM) and on NASDAQ in New York (ticker: TRMD). For further information, please visit www.torm.com.

Safe Harbor statements as to the future

Matters discussed in this release may constitute forward-looking statements and may be more detailed than regular practice. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and statements other than statements of historical facts. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although TORM believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, TORM cannot guarantee that it will achieve or accomplish these expectations, beliefs or projections.
Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward- looking statements include the conclusion of definitive waiver documents with our lenders, the strength of the world economy and currencies, changes in charter hire rates and vessel values, changes in demand for “tonne miles” of oil carried by oil tankers, the effect of changes in OPEC’s petroleum production levels and worldwide oil consumption and storage, changes in demand that may affect attitudes of time charterers to scheduled and unscheduled dry-docking, changes in TORM’s operating expenses, including bunker prices, dry-docking and insurance costs, changes in the regulation of shipping operations, including requirements for double hull tankers or actions taken by regulatory authorities, potential liability from pending or future litigation, domestic and international political conditions, potential disruption of shipping routes due to accidents and political events or acts by terrorists.

Risks and uncertainties are further described in reports filed by TORM with the US Securities and Exchange Commission, including the TORM Annual Report on Form 20-F and its reports on Form 6-K.

Forward-looking statements are based on management’s current evaluation, and TORM is only under an obligation to update and change the listed expectations to the extent required by law.

ACADIA (ACAD) Announces $86 Million Equity Financing

–Proceeds to Support Completion of Pimavanserin Phase III Program–

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced a private placement equity financing pursuant to which ACADIA will receive gross proceeds of $86.4 million from the sale of its securities. Shares of ACADIA’s common stock will be sold at $4.43 per share, the closing market price on December 11, 2012. The private placement is expected to close on December 17, 2012 and is subject to the satisfaction of customary closing conditions.

The anticipated proceeds from the private placement will be used primarily to support completion of ACADIA’s Phase III pimavanserin program, including its planned confirmatory Phase III pivotal trial in Parkinson’s disease psychosis.

Jefferies & Company, Inc. and Cowen and Company, LLC acted as joint lead placement agents; JMP Securities LLC acted as co-placement agent in the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

The securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. ACADIA has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the private placement.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson’s disease psychosis. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. All product candidates are small molecules that emanate from discoveries made at ACADIA. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA’s drug discovery and development programs, either alone or with a partner, including the progress of clinical trials, and the clinical benefits to be derived from ACADIA’s product candidates, in each case including pimavanserin. In particular, forward-looking statements include statements regarding the expected proceeds from and timing of the closing of the private placement, the use of proceeds from the private placement, including whether the proceeds will be sufficient to fund the completion of the Phase III program for pimavanserin, including the planned confirmatory Phase III pivotal trial, and the anticipated filing of a registration statement to cover resales of common stock issuable in connection with the private placement. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development, regulatory review and commercialization, including in collaborations with others, the fact that past results of clinical trials may not be indicative of future trial results, and ACADIA’s ability to satisfy the conditions to closing the private placement. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2011 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

DayStar (DSTI) Announces Former Clinton Admin and NM Governor Bill Richardson Joins Board

DayStar Technologies (DSTI) Announces That Former United States Secretary of Energy and Ambassador to the United Nations Under President Clinton’s Administration and the Former Governor of New Mexico, William (Bill) Richardson, Joins Its Board of Directors

KELOWNA, BC — (Marketwire) — 12/12/12 — DayStar Technologies, Inc. (NASDAQ: DSTI) announces a new member to their Board of Directors. Former United States Secretary of Energy, former Governor of New Mexico and Nobel Prize nominee, Bill Richardson, has joined the Board of Directors of DayStar Technologies.

Lorne (Mark) Roseborough, President of DayStar, stated, “Bill Richardson made New Mexico the ‘Clean Energy State’ by requiring utilities to meet 20% of New Mexico’s electrical demand from renewable sources, and established the Renewable Energy Transmission Authority to deliver New Mexico’s world-class renewable resources to market. This level of determination matches DayStar’s commitment in the Global Renewable Energy Industry. Mr. Richardson’s international respect and recognition in this industry will bring proven leadership in assisting DayStar’s execution of its global business model.”

Prior to being elected governor, Mr. Richardson served for 15 years in New Mexico representing the 3rd Congressional District. In 1997 &1998 Mr. Richardson served as the U.S. Ambassador to the United Nations, and he was unanimously confirmed by the U.S. Senate as Secretary of the U.S. Department of Energy under the Clinton Administration.

Daniel Germain, Chairman of the Nomination Committee and founder of the Breakfast Clubs of Canada, stated, “Mr. Richardson, and his diplomatic skills honed through years of public and private service, will complement DayStar’s local, national and international presence. One of the reasons he held the positions of Governor, U.S. Secretary of Energy, and United Nations Ambassador is because of his level of dedication to protecting the rights and improving the quality of life for people everywhere.”

Since leaving his public service office, Mr. Richardson was named chairman of APCO Worldwide’s executive advisory service Global Political Strategies (GPS) and Special Envoy for the Organization of American States (OAS), adding another platform for initiatives within peace and reconciliation in the Western hemisphere. In addition, Mr.Richardson serves as Senior Fellow for Latin America at Rice University’s James A. Baker III Institute for Public Policy and has joined several non-profit and for-profit boards, including Abengoa’s International Advisory Board, the fifth largest biofuels producer in the U.S., WRI World Resources Institute, Refugees International and the National Council for Science and the Environment.

About DayStar Technologies, Inc:

DayStar Technologies, Inc. (DSTI) is a developer of solar photovoltaic products based upon CIGS thin film deposition technology and is currently embarked on a strategy of strategic partnerships to enter new markets within the global renewal energy industry including ownership and construction of solar and renewable power plants. For more information, visit the DayStar website at http://www.daystartech.com/.

For further information contact, William J. Nalley, Orsay Groupe, 305-515-8077, Info@orsaygroupe.com.

Safe Harbor: Statements contained in this news release which are not historical facts may be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words like “believe,” “expect,” “anticipate,” “estimate” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could” or “may.” We undertake no obligation to update any forward-looking statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
William Nalley
Orsay Groupe, Inc.

Gilead Sciences to Acquire YM BioSciences (YMI)

– Adds Selective JAK Inhibitor to Growing Oncology and Inflammation Pipeline –

Gilead Sciences, Inc. (Nasdaq: GILD) and YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) announced today that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. The transaction has received the unanimous approval of YM’s Board of Directors, and values YM at approximately U.S.$510 million, with YM reporting C$125.5 million in cash and cash equivalents as of September 30, 2012. Gilead plans to fund the acquisition with cash on hand. The transaction is expected to close in the first quarter of 2013.

YM’s lead drug candidate, CYT387, is an orally-administered, once-daily, selective inhibitor of the Janus kinase (JAK) family, specifically JAK1 and JAK2. The JAK enzymes have been implicated in a number of disorders including myeloproliferative diseases, inflammatory disorders and certain cancers. YM has reported positive results from a Phase 1/2 clinical trial of CYT387 in 166 patients with myelofibrosis, a life-threatening myeloproliferative disease. Pending completion of the acquisition, Gilead intends to initiate a pivotal Phase 3 clinical trial of CYT387 in myelofibrosis in the second half of 2013.

“This acquisition represents an opportunity to add a complementary clinical program in the area of hematologic cancers to our growing oncology portfolio,” said Norbert W. Bischofberger, PhD, Gilead’s Executive Vice President, Research and Development and Chief Scientific Officer. “Based on promising Phase 2 data, we believe CYT387 could provide important clinical benefit for patients with myelofibrosis, including potential improvements with regard to anemia and decreased dependence on blood transfusions. We look forward to advancing CYT387 into a Phase 3 study as quickly as possible and to exploring its potential in other myeloproliferative diseases with significant unmet medical need.”

Myelofibrosis is a progressive, chronic bone marrow disorder in which the marrow is replaced by fibrous scar tissue, making it difficult for the bone marrow to sufficiently produce blood cells, leading to anemia (low red blood cell count) and thrombocytopenia (low blood platelet count), severe constitutional symptoms and spleen enlargement. JAK inhibitors modulate cytokine-stimulated intracellular signalling and decrease the circulating levels of proinflammatory cytokines associated with the pathogenesis of myelofibrosis.

“This agreement represents a positive outcome both for myelofibrosis patients and for our shareholders. Gilead has the research and development capabilities and the resources needed to more fully realize the potential of CYT387 as a therapeutic advance for myelofibrosis patients and potentially for other indications,” said Dr. Nick Glover, President and CEO of YM.

“Since our acquisition of CYT387 nearly three years ago, YM has made great progress in advancing CYT387 through the clinical, regulatory, manufacturing and business development processes. While Gilead’s acquisition will end a long, varied and interesting journey for YM, we are pleased to have this transaction crystallize the present value of this important therapeutic candidate,” said Mr. David Allan, Chairman of YM.

In recent years, Gilead has sought to expand its R&D expertise in the area of oncology through the appointment of leading cancer researchers and clinicians, the establishment of external scientific partnerships and through strategic acquisitions. Gilead’s lead compound in oncology, idelalisib (formerly referred to as GS-1101), is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform. Five Phase 3 studies of idelalisib in chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin’s lymphoma (iNHL) are progressing.

Gilead is also conducting Phase 2 clinical trials of simtuzumab (formerly referred to as GS-6624), an investigational monoclonal antibody (mAb) candidate targeting the human lysyl oxidase-like 2 (LOXL2) protein, in myelofibrosis, colorectal cancer, pancreatic cancer and certain fibrotic diseases.

CYT387, idelalisib and simtuzumab are investigational products and their safety and efficacy have not yet been established.

Terms of the Transaction

Under the terms of the agreement, upon closing of the proposed transaction, shareholders of YM will receive U.S.$2.95 per common share in cash, and holders of warrants and stock options will receive a cash payment equal to the difference between U.S.$2.95 and the exercise price of such warrant or stock option. The proposed transaction will be completed through a plan of arrangement under the provisions of the Companies Act (Nova Scotia).

The transaction will require the approval of YM shareholders at a special meeting of YM shareholders, to be held as soon as reasonably practicable and in any event on or before February 11, 2013. In addition to YM’s shareholder approval, closing of the transaction is subject to the satisfaction of certain other customary conditions, including court approval of the transaction, and applicable government and regulatory approvals, including expiration or termination of the waiting period under the United States Hart Scott Rodino Antitrust Improvements Act, and the review period under the Competition Act (Canada). The approval of Gilead shareholders is not required in connection with the proposed transaction.

The arrangement agreement contains customary non-solicitation provisions, but permits YM, in certain circumstances, to terminate the arrangement and accept an unsolicited superior proposal, subject to fulfilling certain conditions.

BofA Merrill Lynch and Bloom Burton & Co. serve as financial advisors, and Gowling Lafleur Henderson LLP, Heenan Blaikie LLP and Dorsey & Whitney LLP serve as legal advisors to YM in connection with the transaction. Gilead is advised by Wilson Sonsini Goodrich & Rosati, Professional Corporation and Blake Cassels and Graydon LLP.

About YM

YM BioSciences Inc. is a drug development company primarily focused on advancing CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. Positive interim results have been reported from a Phase 1/2 trial of CYT387 in 166 patients with myelofibrosis. In addition, YM has several preclinical programs underway with candidates from its library of novel compounds identified through internal research conducted at YM BioSciences Australia.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

YM Forward-Looking Statement

This press release may contain forward-looking statements, which reflect YM’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, shareholder approval of the proposed Arrangement; YM’s ability to obtain court, regulatory, and other approvals in connection with the proposed Arrangement; uncertainties as to the timing of the Arrangement; the satisfaction of the conditions precedent to the completion of the Arrangement, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Arrangement; changing market conditions; the successful and timely completion of clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in YM’s ongoing quarterly and annual reporting. Except as required by applicable securities laws, YM undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Gilead Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies’ and members of their senior management team. Forward-looking statements include, without limitation, the ability of Gilead to advance YM’s product pipeline, including CYT387, the possibility that Gilead will be unable to initiate a Phase 3 trial of CYT387 in myelofibrosis as currently anticipated; the possibility of unfavorable results of clinical trials of CYT387, idelalisib and simtuzumab; the expected timing of the completion of the transaction; and the ability to complete the transaction considering the various closing conditions, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: the effects of the transaction on relationships with employees, customers, other business partners or governmental entities; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in Gilead’s Report on Form 10-Q and for the quarter ended September 30, 2012. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Additional Information and Where to Find It

Further information regarding the transaction will be contained in an information circular that YM will prepare and mail to its shareholders in connection with the YM shareholders’ meeting, with closing expected to occur in the first quarter of 2013. YM shareholders are urged to read the information circular once it becomes available, as it will contain important information concerning the proposed transaction. YM shareholders may obtain a copy of the arrangement agreement, information circular, and other meeting materials when they become available at www.sec.gov and www.sedar.com.

This press release is for informational purposes only. It does not constitute an offer to purchase shares of YM or a solicitation or recommendation statement under the rules and regulations of the United States Securities and Exchange Commission or other applicable laws.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com,

follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5

or 1-650-574-3000.

For more information on YM BioSciences, please visit the company’s website at www.ymbiosciences.com or contact James Smith, VP Corporate Affairs at 905.361.9518 or jsmith@ymbiosciences.com

GlobalWise (GWIV) Channel Partner Sycle.net Continues to Deliver New Clients

COLUMBUS, OH — (Marketwire) — 12/12/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today provide an update on the successful Sycle.net (http://web.sycle.net/) clinic expansion growth and ongoing annuity stream billing of the eDocs cloud based software into 215 audiology clinics nationwide. Sycle.net launched the eDocs program on August 1, 2012.

Since 2002, Sycle.net (http://web.sycle.net/) has become an industry leader in hearing care practice management. Sycle.net’s unique web-based solution allows personnel to access patient data anywhere, anytime, from any device. GlobalWise and Sycle.net teamed together earlier this year to co-develop the eDocs (http://web.sycle.net/products/edocs/) cloud-based ECM solution specifically for the SMB hearing care industry.

“eDocs represents the ease and simplicity of integrating the cloud-based Intellivue™ software into existing ERP software solutions,” stated William “BJ” Santiago, CEO of GlobalWise. “We have grown our installed base and annuity stream billing with Sycle.net to 215 new clinic installations in the last couple of months. The GlobalWise cloud-based ECM software is designed through open APIs to be compatible in almost any configuration or installation. The integration with Sycle.net’s software instantly enabled Sycle.net to expand their clinic base into new SMB audiology clinic markets and continues to service their Enterprise tier audiology markets as well. The new SMB market was previously not available due to the high cost of service and focus on larger clients.”

“The release of eDocs has been Sycle.net’s most successful product release since we launched our core practice management system over ten years ago,” stated Tom Harris, Executive Director of Sales / Product Manager. “We have never seen our users adopt an ancillary product so quickly. Since August 1, 2012, we have rolled eDocs out into 215 clinics across the US. We expect to have eDocs up and running in over 1,500 clinics globally by December of next year. Working with the team over at Intellinetics has been a pleasure. They have become a part of Sycle.net’s extended family and have undoubtedly contributed to the success of eDocs.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Community Bankers (BTC) Essex Bank Terminate Regulatory Agreement

GLEN ALLEN, Va., Dec. 11, 2012 /PRNewswire/ — Community Bankers Trust Corporation, the holding company for Essex Bank (NYSE MKT: BTC), announced today that the Federal Reserve Bank of Richmond and the Bureau of Financial Institutions of the Virginia State Corporation Commission have terminated their written agreement with the Company and the Bank.  The parties had entered into the written agreement on April 21, 2011.

Rex L. Smith, III, President and Chief Executive Officer of the Company and the Bank, stated, “I am very pleased and excited by our complete release from this enforcement action.  Our talented and dedicated employees have worked diligently in conjunction with our primary regulators to remove old obstacles and to clean up the balance sheet in order to ensure a solid foundation for a successful banking franchise in the Mid-Atlantic markets.”

Mr. Smith added, “When I became interim Chief Executive Officer two years ago, we reported a net loss of $24.5 million through the third quarter of 2010, and we had over $43 million of non-performing loans. We had a material weakness in our financial reporting, and we had ineffective planning with no resolution in sight.  As a result, our stock traded at that time at levels as low as 70 cents per share.  Since that time, despite a difficult economy, we have been able to dramatically affect the position of the Company and make it an attractive investment.  The release from the written agreement is the final chapter to one of the greatest turn-around stories in community banking today.  I am happy for all of us here to have been able to be a part of it and, as always, we remain committed to returning long-term value for our stockholders.”

The Federal Reserve publicly announced the termination of the written agreement, which was effective December 5, 2012, in a press release dated December 11, 2012.

About Community Bankers Trust Corporation

The Company is the holding company for Essex Bank, a Virginia state bank with 24 full-service offices, 13 of which are in Virginia, seven of which are in Maryland and four of which are in Georgia.  The Company also operates one loan production office.  Additional information is available on the Company’s website at www.cbtrustcorp.com.

Forward-Looking Statements

This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks and uncertainties. These forward-looking statements include, without limitation, statements with respect to the Company’s operations and goals. Actual results may differ materially from those included in the forward-looking statements due to a number of factors, including, without limitation, the effects of and changes in the following: the quality or composition of the Company’s loan or investment portfolios, including collateral values and the repayment abilities of borrowers and issuers; assumptions that underlie the Company’s allowance for loan losses; general economic and market conditions, either nationally or in the Company’s  market areas; the ability of the Company to comply with regulatory actions, and the costs associated with doing so; the interest rate environment; competitive pressures among banks and financial institutions or from companies outside the banking industry; real estate values; the demand for deposit, loan, and investment products and other financial services; the demand, development and acceptance of new products and services; the Company’s compliance with, and the timing of future reimbursements from the FDIC to the Company under, shared loss agreements with the FDIC; assumptions and estimates that underlie the accounting for loan pools under the shared loss agreements; consumer profiles and spending and savings habits; the securities and credit markets; costs associated with the integration of banking and other internal operations; management’s evaluation of goodwill and other assets on a periodic basis, and any resulting impairment charges, under applicable accounting standards; the soundness of other financial institutions with which the Company does business; inflation; technology; and legislative and regulatory requirements. Many of these factors and additional risks and uncertainties are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011 and other reports filed from time to time by the Company with the Securities and Exchange Commission. This press release speaks only as of its date, and the Company disclaims any duty to update the information in it.

WebMD (WBMD) Streamlines Business and Expects to Reduce Expenses by $45M

NEW YORK, Dec. 11, 2012 /PRNewswire/ — WebMD Health Corp. (NASDAQ:WBMD), the leading source of health information, announced today a comprehensive program to streamline its operations, reduce costs and better focus its resources on increasing user engagement, improving customer satisfaction and driving innovation. WebMD expects these actions to result in a reduction in annualized operating expenditures of approximately $45 million, including the impact of a workforce reduction of approximately 250 positions, or roughly 14% of the Company’s employees. While most of the workforce reductions will be effective at the end of this year, other cost savings actions will be implemented over the course of the first quarter of 2013. WebMD will continue to provide patients, consumers and physicians with an unmatched breadth of trusted content and valuable tools across its market leading multi-screen platform.

Cavan Redmond, Chief Executive Officer of WebMD, said, “WebMD’s value proposition for users continues to be very strong. Becoming leaner and more nimble will enable the Company to extend our leadership in this highly dynamic and increasingly demanding marketplace. In addition, anticipated changes in U.S. healthcare will provide meaningful new opportunities to link the needs of patients, consumers and healthcare professionals to enable them to navigate their care.  We are moving swiftly to implement these operational changes and new market initiatives.”

As part of this program, WebMD is streamlining its sales and delivery processes to enable better collaboration with our sponsor and agency clients.  Across the entire company, there will be a sharper focus on prioritizing resources and investment to key areas of future growth.

The Company anticipates it will record a pre-tax restructuring charge of approximately $6 million to $8 million in the fourth quarter of 2012 primarily for severance and other costs related to this cost reduction initiative. This charge was not contemplated in the Company’s previously issued 2012 financial guidance.

About WebMD
WebMD Health Corp. (NASDAQ: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers, and health plans through our public and private online portals, mobile platforms and health-focused publications.

The WebMD Health Network includes WebMD Health, Medscape, MedicineNet, eMedicineHealth, RxList, theheart.org, Medscape Education and other owned WebMD sites.

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding:   the expected effects of the planned streamlining of our operations, including the amounts and timing of expected reductions in expenditures and the expected benefits to our operating efficiency; and market opportunities and our ability to capitalize on them. These statements speak only as of the date of this press release, are based on our current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements.  These risks and uncertainties include those relating to:  market acceptance of our products and services; our relationships with customers and other factors affecting their use of our products and services, including regulatory matters affecting their products; our ability to successfully implement, in the anticipated timeframes, the planned streamlining of our operations and related expense reductions; our ability to attract and retain qualified personnel; and changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet and information technology industries.  Further information about these matters can be found in our Securities and Exchange Commission filings. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

Cardiome (CRME) Reaches Agreement With Merck to Retire Debt and Close Line of Credit

VANCOUVER, British Columbia, Dec. 11, 2012 (GLOBE NEWSWIRE) — Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today announced that the company has reached an agreement with Merck to settle its debt obligations stemming from the companies’ collaboration and license agreement for vernakalant, signed in April 2009.

Under the terms of the settlement agreement, Cardiome will pay Merck $20 million on or before March 31, 2013, to settle its outstanding debt of $50 million owed to Merck. The payment will be made from Cardiome’s existing cash balance, which totalled $53.6 million at the end of September 2012. Pursuant to the vernakalant collaboration and license agreement Merck had granted Cardiome an interest-bearing credit facility of up to $100 million, secured by a first priority security interest in the company’s vernakalant patents throughout the world and all associated proceeds. The settlement between Cardiome and Merck will terminate the credit facility and, upon payment of the $20 million settlement amount, will release and discharge the collateral security taken in respect of the advances under the line of credit.

“Complete resolution of our $50 million debt obligation to Merck removes a significant financial and operational overhang for Cardiome,” stated William Hunter, M.D., Cardiome’s interim CEO. “I am pleased with the progress we are making on the transfer of vernakalant back to Cardiome and we appreciate the efforts of Merck to make the transition of BRINAVESS^TM as smooth as possible for our doctors and patients in Europe and other markets. Merck’s commitment to our product and our patients, and to putting Cardiome on a stable financial footing, will allow us to manage our business unencumbered and realize the commercial and medical value of vernakalant.”

In September 2012, Merck informed Cardiome that Merck (through two of its subsidiaries) would return the global marketing and development rights for both the intravenous (IV) and oral formulations of vernakalant to Cardiome. Vernakalant IV is marketed under the brand name BRINAVESS^TM. BRINAVESS^TM has received approval in the European Union and certain other markets worldwide for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults: for non-surgery patients with AF of seven days or less and for post-cardiac surgery patients with AF of three days or less. Vernakalant IV is not approved for use in the United States or Canada.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS^TM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Risks, uncertainties and factors that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks, uncertainties and factors related to the fact that: we, together with our collaborative partners, may not be able to successfully develop all or any of our current or future products and may not be able to  obtain regulatory approval in targeted indications for our current or future products in all markets; we may not achieve or maintain profitability; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital as and when required; we depend on our collaborative partners to perform their obligations under licensing or other collaborative agreements; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; any of our products that obtain regulatory approval will be subject to extensive post-market regulation that may affect sales, marketing and profitability; any of our products that are successfully developed may not achieve market acceptance; we rely on third parties for the continued supply and manufacture of our products and have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters, including with respect to our ability to protect our intellectual property; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com.  Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

CONTACT: For Further Information:
         Cardiome Investor Relations
         (604) 676-6993 or Toll Free: 1-800-330-9928
         Email: ir@cardiome.com

Pernix Therapeutics (PTX) Announces Agreement to Acquire Somaxon

Somaxon Shareholders to Receive $25 Million in Pernix Common Stock Pernix Management to Host a Conference Call Today at 9:00 a.m. EST

Pernix Therapeutics Holdings, Inc. (“Pernix”) (NYSE MKT: PTX) and Somaxon Pharmaceuticals, Inc. (“Somaxon”) (NASDAQ: SOMX) today announced that they have entered into a definitive merger agreement for Pernix to acquire Somaxon in a stock-for-stock transaction with a total equity value of $25 million.

Under the terms of the agreement, which has been unanimously approved by the boards of directors of both companies, Somaxon stockholders will receive aggregate consideration equal to $25 million in Pernix common stock. The number of shares of Pernix common stock to be issued to the stockholders of Somaxon will be based on the volume-weighted average price of Pernix’s common stock over the 30 day period ending on the day immediately prior to the closing of the proposed merger, subject to limitations on the maximum and minimum number of shares of Pernix common stock issuable in the transaction based on a price range of $6.00 to $9.00 per share.

Cooper Collins, President and CEO of Pernix, said, “The acquisition of Somaxon is another important step in the growth strategy of Pernix, which is expected to continue to expand our product portfolio, in addition to our recently announced agreements to acquire Cypress Pharmaceuticals and Hawthorn Pharmaceuticals. Somaxon’s product Silenor, which is a non-seasonal product, broadens our branded product line and may also have potential as an OTC product in the future.”

Silenor® (doxepin) is approved for the treatment of insomnia characterized by difficulty with sleep maintenance and is not a controlled substance. In clinical trials, Silenor demonstrated maintenance of sleep, including into the seventh and eighth hours of the night, with no meaningful evidence of next day residual effects and an overall adverse events profile that was comparable to placebo.

On a trailing 12-month basis as of September 30, 2012, Somaxon had net sales related to Silenor of approximately $11.7 million. Pernix expects net sales from Silenor on an annualized basis to be in the range of approximately $10 million to $15 million and earnings before interest, taxes, depreciation and amortization (EBITDA) resulting from such Silenor net sales in the range of approximately $5 million to $10 million.

Richard W. Pascoe, Somaxon’s President and Chief Executive Officer, said, “We believe this acquisition will provide the opportunity to more fully capitalize on the Silenor brand. Moreover, with Pernix’s recently announced acquisition of Cypress and Hawthorn, we believe that the combined entity, with its broad platform of branded, generic and OTC products, represents long-term value for the benefit of all of our stockholders. We look forward to working with the Pernix management team as we integrate Somaxon with Pernix.”

The acquisition is subject to the approval of Somaxon’s shareholders and the satisfaction of other terms and conditions. Stifel Nicolaus Weisel is acting as financial advisor to Somaxon in the transaction.

Conference Call

The management of Pernix will host a conference call today at 9:00 a.m. EST to discuss the proposed acquisition of Somaxon Pharmaceuticals. The conference call will feature remarks from Cooper Collins, President and Chief Executive Officer, and David Becker, Chief Financial Officer. To participate in the live conference call, please dial (877) 312-8783 (U.S.) or (408) 940-3874 (International), and provide passcode 80437861. A live webcast of the call will also be available on the investor relations section of the Company’s website, www.pernixtx.com. Please allow extra time prior to the webcast to register and download and install any necessary audio software.

A replay of the call will be available through December 18, 2012. To access the replay, please dial (855) 859-2056 (U.S.) or (404) 537-3406 (International), and provide passcode 80437861. An online archive of the webcast will be available on the Company’s website for 30 days following the call.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. The Company manages a portfolio of branded and generic products. The Company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC, and a family of treatments for cough and cold (BROVEX®, ALDEX® and PEDIATEX®). The Company’s branded products for gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer disease, and REZYST™, a probiotic blend to promote dietary management. In addition, a product candidate utilizing cough-related intellectual property is in development for the U.S. OTC market. The Company promotes its branded pediatric and gastroenterology products through its sales force. Pernix markets its generic products through its wholly-owned subsidiary, Macoven Pharmaceuticals. The Company’s wholly-owned subsidiary, Great Southern Laboratories, manufactures and packages products for the pharmaceutical industry in a wide range of dosage-forms. Founded in 1996, the Company is based in The Woodlands, TX.

Additional information about Pernix is available on the Company’s website located at www.pernixtx.com.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Somaxon’s product Silenor, available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

Important Safety Information About Silenor

Because sleep disturbances may be caused by underlying physical and/or psychiatric disorders, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7-10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.

Patients should only take Silenor when they are prepared to get a full night’s sleep. Silenor should be taken within 30 minutes of bedtime, and patients should confine their activities after ingestion to those necessary to prepare for bed. Patients should not consume alcohol or take other drugs that cause drowsiness with Silenor. Co-administration of monoamine oxidase inhibitors (MAOIs) with Silenor has not been studied and is not recommended. Patients should not take Silenor if they have untreated narrow angle glaucoma, severe urinary retention, severe sleep apnea or hypersensitivity to any of the ingredients in Silenor. Patients should avoid engaging in hazardous activities such as operating a motor vehicle or heavy machinery at night after taking Silenor, and patients should be cautioned about potential impairment in the performance of such activities that may occur during the day following ingestion. Before taking Silenor, patients should tell their doctors if they have a history of depression, mental illness or suicidal thoughts.

Hypnotics have been associated with complex behaviors such as sleep driving, preparing and eating food, making phone calls, or having sex. Drowsiness, upper respiratory tract infections and nausea were the most common adverse events observed in Silenor clinical trials.

Cautionary Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the completion of the proposed merger, future financial and operating results, benefits and synergies of the proposed merger, potential cost savings, future opportunities for the combined company and any other statements about Pernix’s or Somaxon’s management’s future expectations, beliefs, goals, plans or prospects. Statements including words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “view,” “hope,” “could,” “will,” “should,” “expect,” “anticipate,” “believe,” “seek,” “target” or similar expressions should also be considered forward-looking statements. Because these statements reflect current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties and assumptions as to future events that may not prove to be accurate. No assurances can be given that the parties to the proposed merger will be able to complete the transaction when anticipated or at all, nor does Pernix or Somaxon provide any assurances regarding its future performance, ability to realize future benefits, cost savings and synergies of the proposed merger or future opportunities for the combined company. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: failure of Somaxon stockholders to approve the proposed transaction; the challenges and costs of closing, integrating, restructuring and achieving anticipated cost savings and synergies; the ability to retain key employees; and other economic, business, competitive, and/or regulatory factors affecting the businesses of Somaxon and Pernix generally. In addition to these factors, investors should note the other factors described under the caption “Risk Factors” in Pernix’s and Somaxon’s respective Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein. These forward-looking statements speak only as of the date hereof. Pernix and Somaxon disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this document.

Important Information For Investors and Securities Holders

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. In connection with the proposed transaction between Pernix and Somaxon, Pernix plans to file with the Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 that will include a prospectus of Pernix that will also constitute a proxy statement of Somaxon. Pernix and Somaxon also plan to file with the SEC other relevant documents in connection with the proposed agreement. INVESTORS AND SECURITIES HOLDERS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT PERNIX, SOMAXON, THE PROPOSED MERGER AGREEMENT AND RELATED MATTERS.

Investors and security holders will be able to obtain free copies of the proxy statement/prospectus and other documents filed with the SEC by Pernix and Somaxon (when available) through the website maintained by the SEC at www.sec.gov. Investors and security holders will be able to obtain free copies of the documents filed with the SEC by Pernix on Pernix’s website at www.pernixtx.com or by contacting Pernix Investor Relations at (800) 793-2145 ext. 3002. Investors and security holders will be able to obtain free copies of the documents filed with the SEC by Somaxon on Somaxon’s website at www.somaxon.com or by contacting Somaxon Investor Relations at (858) 876-6500.

Participants in the Acquisition of Somaxon

Pernix and Somaxon and their respective directors, executive officers, members of management and employees may be deemed, under the rules of the SEC, to be “participants in the solicitation” of proxies from the stockholders of Somaxon in connection with the proposed merger and a description of their direct and indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available. Information regarding Pernix’s directors and executive officers and their beneficial ownership of Pernix common stock as of April 23, 2012 is available in its proxy statement filed with the SEC by Pernix on April 27, 2012, and information regarding Somaxon’s directors and executive officers and their beneficial ownership of Pernix common stock as of April 9, 2012 is available in its proxy statement filed with the SEC by Somaxon on April 23, 2012. You can obtain free copies of these documents using the contact information above.

BG Medicine (BGMD) Obtains CE Mark for CardioSCORE(TM) Test in Europe

Innovative Blood Test for the Prediction of Major Cardiovascular Events Expected to Launch in the First Half of 2013

WALTHAM, Mass., Dec. 11, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that it has obtained a CE Mark enabling the commercial sale of the CardioSCORE™ test in the EU and other countries that recognize the CE Mark. The CardioSCORE test is the company’s patented diagnostic blood test designed to dramatically improve risk prediction of major cardiovascular events beyond traditional risk factor assessments, such as the Framingham Risk Score and European SCORE.

The CardioSCORE test is performed on a standard blood sample and utilizes algorithmic analysis to combine the results of seven reimbursed protein assays. The test involves an independent scoring system that yields a quantitative result ranging from 0.0 to 10.0, with higher values indicating elevated risk for a major cardiovascular event in the subsequent 3 years and with each 1.0 point increment representing a 30% increase in relative risk. In the 6,600 patient BioImage Study cohort, the primary clinical validation study for the CardioSCORE test, among those who experienced a near-term major cardiovascular event during follow-up, only 26% were identified as being at high risk at baseline by traditional risk factors, whereas 54% percent were identified as being at high risk upon addition of their CardioSCORE result (p<0.0001).

“We are thrilled to bring the benefits of the CardioSCORE test to patients and physicians in Europe. We believe this test will be a pivotal and disruptive game-changer in the primary prevention of major cardiovascular events and treatment of disease, representing a major advancement over the diagnostic tools clinicians have used for the past 15 years,” said Eric Bouvier, President and Chief Executive Officer of BG Medicine. “The majority of cardiovascular events occur among patients who are asymptomatic, and current risk factor assessment methods simply miss too many patients with hidden subclinical risk, delaying appropriate therapy and effective monitoring of response to such therapy. The CardioSCORE test will identify individuals at elevated risk for heart attack and stroke, enabling preventive intervention. We are working aggressively to launch the test in the first half of 2013 in Europe in collaboration with specialty laboratory partners.”

“The CardioSCORE test may have the potential to help improve the care of many people by providing a simple, accurate and clinically meaningful score to assess an individual’s risk for near-term major cardiovascular events,” said Valentin Fuster, MD, PhD, Professor of Cardiology and Director of Mount Sinai Heart.

Last month, investigators at the American Heart Association (AHA) Scientific Sessions 2012 presented the results of several analyses of the CardioSCORE test performance in the BioImage Study. The presentations by investigators from the Mt. Sinai School of Medicine and the Baptist Hospital of Miami highlighted the predictive value of the test in assessing risk for near-term major cardiovascular events across a broad and diverse community-dwelling population. A summary of these findings is available here: http://investor.bg-medicine.com/releases.cfm.

“Obtaining the CE Mark for the CardioSCORE test is not only a significant milestone in the prevention and treatment of cardiovascular disease but also a critical advancement in our company’s continued transformation into a full-scale commercial organization,” continued Mr. Bouvier. “BG Medicine now has two products covering the continuum of heart disease diagnostics, positioning us strongly to drive the clinical usage of our important diagnostic tests for millions of patients who will benefit from them throughout the world.”

The CardioSCORE test is not yet available commercially in the United States. BG Medicine is continuing its active discussions with the US Food and Drug Administration regarding 510(k) clearance for the test in the United States.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the development and commercialization of novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company has two products: the BGM Galectin-3^® test for use in patients with chronic heart failure is available in the United States and Europe; and the CardioSCORE™ test for the risk prediction of major cardiovascular events will be launched in Europe in the first half of 2013. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this news release address our belief in the significant potential of the CardioSCORE test to provide valuable information about an individual’s risk of experiencing near-term major cardiovascular events; our belief in the importance of receiving CE Mark in the EU in order to foster widespread adoption of the CardioSCORE test and as a means of broadening our commercialization efforts for our diagnostics tests generally; our belief that there is a critical need for a simple and easy-to-use blood test to more accurately determine patients’ risks for near-term major cardiovascular events. Forward-looking statements are based on management’s current expectations and involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         (781) 434-0210